Parr Maria K, Gütschow Michael, Daniels Jörg, Opfermann Georg, Thevis Mario, Schänzer Wilhelm
Center for Preventive Doping Research, Institute of Biochemistry, German Sport University Cologne, Carl-Diem-Weg 6, 50933 Cologne, Germany.
Steroids. 2009 Mar;74(3):322-8. doi: 10.1016/j.steroids.2008.11.006. Epub 2008 Nov 17.
The product Orastan-A from Gaspari Nutrition was analyzed for its steroid content. According to the labeling, it is supposed to contain "5a-Androstano[2,3-c]furazan-17b-tetrahydropyranol ether", also called furazadrol-THP ether. The GC-MS analyses of the liberated steroids (after extraction from the capsule matrix and cleavage of the THP ether, TMS-derivative and underivatized) revealed mass spectra of two components, both inconsistent with the labeling. Thus, the steroids were characterized by different analytical techniques such as mass spectrometry, nuclear magnetic resonance spectroscopy and X-ray crystal structure analysis. They were identified as 17beta-hydroxyandrostano[3,2-c]isoxazole and -[2,3-d]isoxazole.
对加斯帕里营养公司的产品奥拉斯坦 - A进行了类固醇含量分析。根据标签,它应该含有“5α - 雄甾烷[2,3 - c]呋咱 - 17β - 四氢吡喃醚”,也称为呋咱地罗 - THP醚。对释放出的类固醇进行气相色谱 - 质谱分析(从胶囊基质中提取并裂解THP醚、制成TMS衍生物和未衍生化后)显示有两种成分的质谱图,均与标签不符。因此,通过质谱、核磁共振光谱和X射线晶体结构分析等不同分析技术对这些类固醇进行了表征。它们被鉴定为17β - 羟基雄甾烷[3,2 - c]异恶唑和 - [2,3 - d]异恶唑。